List of Cell Therapies Companies in Germany - 30

ActiTrexx GmbH is a new biotech start up and was founded in 2020. Our vision is to offer a curative cellular therapy to prevent inflammatory reactions in conditions like GvHD, solid organ transplantation and autoimmune diseases. Regulatory T cells (Treg) - natural guardian cells of the immune system - are the key players of our cell-based drug product. Isolated Treg are activated ex vivo via specific methods and administered to patients intravenously. Unlike other comparable approaches, activated Treg (ATreg) will not be expanded in vitro, protecting them against a possible loss of function. Thus, ATreg is a safe and efficient treatment option for transplanted patients preventing and providing substantial decrease of GvHD severity and related mortality as well. The founders of ActiTrexx GmbH combine many years of unique experience in basic research, biotechnology, clinical application and pharmaceutical development. The management team is supported and complemented by a strong network of collaborators, advisors and key opinion leaders as well as experienced managers.

Akribion Genomics discovers novel groundbreaking CRISPR nucleases and develops them into a new class of genetics-based cancer therapies and advanced genome editing tools. Akribion Genomics' flexible CRISPR-based gene editing technology platform features distinct technology families (G-dases®) with broad application in Industrial Biotechnology (and Agriculture), and offers a groundbreaking technological advantage for therapeutic and diagnostic solutions. Akribion Genomics is committed to using its technology with high ethical standards to improve products, processes and medical treatments. Our mission is to enable new treatment approaches in oncology by employing novel CRISPR technology that allows targeted cell depletion using RNA biomarkers. On top, we aim to provide access to advanced CRISPR genome editing technology with freedom-to-operate. All this is summarized in our motto and brand "Gediting". Akribion Genomics is a company in founding and soon-to-be spin-off of BRAIN Biotech AG, a renowned international group of companies providing innovative biobased products and solutions to industry.

ARTCLINE GmbH develops innovative therapy methods for intensive care medicine based on immune cells. Our current main project is the development of the so-called ARTICE technology for the treatment of bacterial sepsis. ARTCLINE's vision is the development of innovative immune cell-based therapy approaches and to make the technology available to physicians and hospitals worldwide. The safety and effectiveness of the therapy is our top priority. Our extensive cell biological, clinical and industrial experience in the fields of immunology, sepsis diagnostics and therapy help us to realize our vision. Together with scientists and partners, we focus our research activities on the root causes and correlations of sepsis. For many years, the founders and the team of ARTCLINE GmbH have been successfully involved in the transfer of medical inventions from university research to industrial application. We have an extensive network and long standing experience in the development and successful marketing of medical devices and drugs.

Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Our products and services are designed to benefit people and improve their quality of life. At the same time, we aim to create value through innovation, growth and high earning power. Our products help address some of today’s biggest challenges, including global population growth, an aging society and the need to make efficient – and, wherever possible, sustainable – use of natural resources. In line with our mission “Bayer: Science For A Better Life,” we aim to improve people’s quality of life by preventing, alleviating or curing diseases. We also help provide an adequate supply of high-quality food, feed and renewable plant-based raw materials. For these endeavors, we focus on developing and successfully commercializing innovative products and solutions based on scientific knowledge.

Bielefeld University is a Higher Education institution that provides academic programs and conducts research.

BioNTech is a global next generation immunotherapy company aspiring to translate science into survival. Around 6.100 pioneers currently work with us, employing a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Our broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor (CAR) T cells, several protein-based therapeutics, including bispecific immune checkpoint modulators, targeted cancer antibodies and antibody-drug conjugate (ADC) therapeutics, as well as small molecules.   Based on our deep expertise in mRNA vaccine development and in-house manufacturing capabilities, we are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. To learn more about us, please visit www.BioNTech.com. Our privacy statement can be found here:  https://www.biontech.com/int/en/home/data-privacy-statement.html Our imprint can be found: https://www.biontech.com/int/en/home/imprint.html

c-LEcta is a global biotechnology company specializing in the development, production and distribution of enzyme products. The company uses world-class enzyme engineering and production technologies to provide its partners in the food and pharmaceutical industries with superior biotechnological solutions for innovative industrial applications. c-LEcta is part of the Kerry Group.

CO.DON ist ein biopharmazeutisches Unternehmen und Hersteller von Zelltransplantaten. Mit mehr als 30 Jahren Erfahrung im Bereich Tissue Engineering liegt der Fokus auf der Entwicklung, Herstellung und Vermarktung von regenerativen, gelenkerhaltenden Zelltherapien zur Behandlung von Knorpeldefekten in Gelenken mit körpereigenen Zellen. Mission und Leidenschaft der Mitarbeiter:innen der CO.DON ist es, Patient:innen durch eine personalisierte Knorpelzelltherapie ein aktives Leben zu ermöglichen. Seit der ersten Behandlung im Jahr 1997, wurden mittlerweile über 19.000 Patient:innen mit den Produkten der CO.DON behandelt. CO.DON hat ihren Hauptsitz in Deutschland und ist darüber hinaus in den Niederlanden sowie mit Vertriebspartnerschaften in Österreich und Großbritannien tätig. In Einklang mit der Unternehmensvision arbeitet CO.DON aktiv daran ihr EU-weit zugelassenes Arzneimittel in weiteren Ländern Europas und damit mehr Patient:innen zugänglich zu machen. CO.DON ist ein Unternehmen der ReLive Biotechnologies. Das global agierende Biotechnologieunternehmen wurde 2021 mit dem Ziel gegründet, den Bereich der Biotechnologie und Zelltherapie nachhaltig zu beeinflussen und die Behandlung von orthopädischen und rekonstruktiven Erkrankungen zu revolutionieren.

Complement Therapeutics GmbH (CTx) is an early-stage biotechnology company focused on the research and development of novel therapeutics for complement-mediated diseases. The Company is a spinout from the University of Manchester and is based on the pioneering research of its founders into novel targets within the complement cascade. Our lead investigational product (CTx001) is being evaluated as a potential gene therapy for dry age-related macular degeneration/geographic atrophy, a leading cause of blindness. Additional programmes will evaluate potential therapeutic opportunities in other complement-mediated conditions. The Company is also developing a unique quantification methodology, the Complement Precision Medicine (CPM) platform, to enable quantification of over 30 complement cascade proteins enabling more precise diagnosis and monitoring of disease.

We at CYTENA strive to empower our customers to serve patients faster and better. To accelerate workflows and bring new insights into biotherapeutic drug development, we provide precise control of individual cells through automation and microtechnology. Our instruments offer automated isolation of single cells with assurance of clonality and selection based on cell morphology. We can isolate many common cell types including bacteria. Our high viability rates make our instruments compatible with cell line development, single cell analysis, and other downstream applications. Most of the top ten largest pharmaceutical companies have successfully integrated cytena instruments into their workflows to quickly produce monoclonal cell lines for antibody development with minimal risk of cross-contamination. cytena instruments are also used for academic research for various topics including cancer, autoimmune disease and genomic research. Our instruments provide many benefits including: Assurance of clonality Every single cell isolated is imaged to provide assurance of clonality. The image sequence is assigned to the well of the deposited cell and stored for documentation. Viability Our instruments gentle handling routinely achieves high cell viability without the need for cell labelling. Purity A disposable cartridge is the only component in contact with the cells ensuring no cross-contamination between samples and no cleaning routines. Easy to use and flexible Our instruments and software are intuitive, user friendly, and can be readily implemented into existing structures and workflows. Interested in joining our team? cytena is a young, dynamic and highly motivated team. We are looking for new team members who also have interest in developing new and innovative products. Feel free to contact us if you have any inquiries on current open positions.

Evotec is a biotechnology company that is committed to advancing drug discovery and development. Through flexible business models, we collaborate with pharmaceutical companies, biotechs, foundations, and government agencies on a substantial scale. We believe that by working together, we can make a difference in the lives of patients. Our Pipeline Co-Creation model represents our adaptable, multi-modality, fully integrated end-to-end approach to drive collaborations and services across all phases of drug discovery and development – from discovery of novel targets to achieving Proof of Concept in the clinic and into commercial manufacturing. We aspire to contribute data-driven disease understanding and early disease relevance in humans to bring the probability of success up. We select the right modality, which is then propelled forward on our platforms by our passionate people striving for the fastest and most effective ways towards patient impact. This is enabled by convergence of human ingenuity with data and AI. We also offer specific solutions, products, and CRO/CDMO-like services, always in support of the Biopharma R&D innovator. Our more than 4,000 scientists work closely with numerous partners concurrently, delivering fully integrated research and development portfolios or individual projects with the highest quality standards and efficiency, coupled with great science, passion, engagement, and communication.

More than six hundred years ago, the first German university was founded in Heidelberg. Today, it attracts international acclaim for its life sciences – especially for medicine. As one of Europe’s largest and most modern medical centers, Heidelberg University Hospital’s 46 specialist departments offer medical care of the highest international standards in all areas of specialty with a focus on oncology care and on other diseases that require complex treatments. Heidelberg University Hospital’s active collaboration with national research facilities attracts patients from many countries worldwide.

Heinrich Heine University Düsseldorf is a Higher Education institution that offers a wide range of academic programs and research opportunities.

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors; and IMA204, an anti-tumor therapy that targets the malignant tumor cell. Its TCR Bispecifics product candidates include IMA401, a cancer testis antigen for the treatment of solid tumor; and IMA402 for the treatment of solid and hematological malignancies. The company also develops IMA101, a multi-target precision immunotherapy; and IMA301, an off-the-shelf ACT. It has a strategic collaboration agreement with GlaxoSmithKline plc to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications; Amgen Inc.; and MorphoSys to develop novel antibody-based therapies against various cancer antigens that are recognized by T cells. Immatics N.V. is headquartered in Tubingen, Germany.

The Max Planck Institute of Quantum Optics is a forefront research organizations in the fields of quantum physics and photonics, with light-matter interaction at its core. In five different research areas excellent scientists from all corners of the world are working together in an open and diverse environment, breaking the ground to what could become another revolution in science. Our laboratories are amongst the best equipped in the world and our scientific culture and spirit is based on freedom and trust, both allowing our scientists to reach the most ambitious objectives.

Medigene AG (FSE: MDG1) is a leading immuno-oncology platform company dedicated to developing T-cell therapies to effectively eliminate cancer. Its end-to-end technology platform is built on multiple proprietary exclusive product development and product enhancement technologies, and allows Medigene to create best-in-class differentiated, T cell receptor engineered T cell (TCR-T) therapies for multiple solid tumor indications that are optimized for both safety and efficacy. This platform provides product candidates for both its in-house therapeutics pipeline and partnering.

Paul-Ehrlich-Institut is a healthcare regulatory agency that oversees pharmaceuticals, approves vaccines, conducts biomedical research, and protects public health.

We at PL BioScience are experts in cell culture supplements derived from human Platelets. Our mission is to enhance the advances in cellular research and therapy with one forward-looking Technology: ELAREM™. The ELAREM™ Platform unites tailored cell culture supplements based on Human Platelet Lysate. The human origin combined with a rich growth factor content not only supports cell growth, but also enables various applications: The products cover all needs of cell expansion in academic research, pre-clinical research and cellular therapy. This ensures seamless transitions in regenerative medicine – from lab to patients in need. Our story goes back to 2015 and the idea to deliver animal component-free cell culture supplements. Today, we have changed the possibilities of cell expansion: Researchers switch from Fetal Bovine Serum to our animal suffering-free products. Stem Cell Therapy benefits the regeneration potential of our platelet-derived products. And we keep moving forward. Let's create the future of cell expansion together and join us on our mission.

Our commitment to scientists is to support them in making new scientific discoveries and groundbreaking research within the life sciences and gene therapy. It is our underlying mission, to help progress new therapies safely, quickly and affordably, so together we can provide solutions to people suffering from poor health and affected by disease every day. PROGEN is made up of a team of experts within AAV and the life sciences and is partnered with gene therapy experts worldwide. We are more than just a manufacturer of antibodies, proteins and ELISAs kits. We strive to understand what scientists need, so we can create solutions and ultimately deliver high quality antibody and exclusive AAV products, which solve your research challenges within academia, biotech and pharma, and ensure PROGEN can continue to be a trusted and reliable partner. Visit our website www.progen.com Imprint: https://bit.ly/3uEZf2h Privacy Statement: https://bit.ly/3dMSgxm

ProtaGene is a world-leading CRO partner for the biopharmaceutical and gene and cell therapy industries. From research through product commercialization, we provide the most advanced, integrated, and complete protein and gene analytic capabilities and packages for biologic therapeutics as well as gene and cell therapy platforms. Our deep history of analytical leadership in protein-based therapeutics stems from the merger of Protagen Protein Services in Europe and BioAnalytix in the US. In 2021, GeneWerk’s unique capabilities in vector safety, integration site analysis, and bioinformatics were added to our portfolio, establishing ProtaGene. Our combined protein- and gene-based analytical platforms make it the leading analytic service provider across the biopharmaceutical and gene and cell therapy development spaces. The organization operates four sites in Europe and North America and works in advanced therapeutic platforms with leading biopharmaceutical and gene therapy companies worldwide.

Ruhr University Bochum is a Higher Education institution that offers research programs and academic degrees.

Seamless Therapeutics is changing the paradigm of gene editing through a pioneering approach to restore health in patients with severe conditions in a safe and precise manner. Our technology platform unlocks the reprogramming of recombinases, a highly versatile class of enzymes. We are applying our proprietary know-how to develop a pipeline of disease-modifying product candidates across a broad spectrum of indications to expand the therapeutic potential of gene editing.

T-CURX is a Biotech company, spun-out from the University Clinics Würzburg, Germany, developing first- and best-in-class personalized immunotherapies on the basis of CAR-T cells. CAR-T cells are a transformative, one-shot, chemotherapy-free targeted and personalized cancer treatment. T-CURX has exclusive licenses for proprietary technologies and CAR-T product opportunities developed in the laboratory of Prof. M. Hudecek, Würzburg, Germany one of the leading European clinical CAR-T cell laboratories. T-CURX leverages several cutting-edge CAR-T engineering technologies, including virus-free transposon based genetic engineering and a highly flexible and modular CAR format. This provides unparalleled flexibility, efficacy, safety, but also scalability for developing CAR-T cells at significantly lower costs than conventional lentivirus-based CAR-T cell manufacturing.

TolerogenixX vision is to innovate Immunosuppression with its newly developed MIC Cell Treatments. MIC Cell Treatment is a curative ATMP approach to achieve a sustained regulation of the immune system in Transplant - and Autoimmune Disease Patients. TolerogenixX has been able to generate strong pre-clinical as well as clinical data in the indications of Transplantation and Autoimmune Diseases e.g. SLE since its foundation in 2016.

Transimmune AG is leading a revolution in dendritic cell therapy having uncovered how dendritic cells are made physiologically in vivo.